Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Analysts' Dramatic Forecast Downgrade

Stock Track11-13

CytomX Therapeutics (NASDAQ:CTMX) shares tumbled 5.20% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The downgrade has raised concerns about the biotech firm's future performance and financial outlook.

According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.

Despite the gloomy outlook, analysts have surprisingly lifted their price target by 15% to US$7.07. However, this increase seems to be at odds with the downgraded forecasts, leaving investors to reassess their investment thesis. The market's negative reaction in pre-market trading suggests that investors are more focused on the potential revenue decline and increased losses rather than the raised price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172648998?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172648998","market":"nz","top_or_hot":-1,"title":"Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Analysts' Dramatic Forecast Downgrade","media":"Stock Track","content":"<p>CytomX Therapeutics (NASDAQ:CTMX) shares tumbled 5.20% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The downgrade has raised concerns about the biotech firm's future performance and financial outlook.</p>\n\n<p>According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.</p>\n\n<p>Despite the gloomy outlook, analysts have surprisingly lifted their price target by 15% to US$7.07. However, this increase seems to be at odds with the downgraded forecasts, leaving investors to reassess their investment thesis. The market's negative reaction in pre-market trading suggests that investors are more focused on the potential revenue decline and increased losses rather than the raised price target.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Analysts' Dramatic Forecast Downgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Analysts' Dramatic Forecast Downgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 21:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CytomX Therapeutics (NASDAQ:CTMX) shares tumbled 5.20% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The downgrade has raised concerns about the biotech firm's future performance and financial outlook.</p>\n\n<p>According to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.</p>\n\n<p>Despite the gloomy outlook, analysts have surprisingly lifted their price target by 15% to US$7.07. However, this increase seems to be at odds with the downgraded forecasts, leaving investors to reassess their investment thesis. The market's negative reaction in pre-market trading suggests that investors are more focused on the potential revenue decline and increased losses rather than the raised price target.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTMX","symbol_name":"CytomX","start_time":0,"source_url":"","article_id":"1172648998","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172648998","pubTimestamp":1763040027,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CytomX Therapeutics (NASDAQ:CTMX) shares tumbled 5.20% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The downgrade has raised...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTMX":"CytomX"},"translate_title":"个股追踪|分析师大幅下调预期后CytomX Therapeutics盘前暴跌5.20%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1},"content_text":"CytomX Therapeutics (NASDAQ:CTMX) shares tumbled 5.20% in pre-market trading on Thursday, following a substantial negative revision to the company's forecasts by analysts. The downgrade has raised concerns about the biotech firm's future performance and financial outlook.\nAccording to the latest analyst reports, CytomX Therapeutics is now expected to face a significant decline in revenues and potentially slip into loss-making territory. Analysts have revised their 2026 revenue forecasts downwards from US$50 million to US$31 million, representing a painful 73% decline in sales compared to the previous year. Additionally, earnings per share (EPS) forecasts have been adjusted, with analysts now predicting losses of US$0.40 per share in 2026, compared to the earlier estimate of US$0.27 per share loss.\nDespite the gloomy outlook, analysts have surprisingly lifted their price target by 15% to US$7.07. However, this increase seems to be at odds with the downgraded forecasts, leaving investors to reassess their investment thesis. The market's negative reaction in pre-market trading suggests that investors are more focused on the potential revenue decline and increased losses rather than the raised price target.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172648998","isCrawlerRequest":true}